Trending storyDeveloping

Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

1 report1 sourceupdated 10 hours ago

Start here

No synthesis yet — start with the coverage timeline below.

Coverage timeline

Follow the coverage to see the different angles.

Oct 23

20:00
clinicaltrials.gov
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy

Heat trend for this story

Heat now 8·Peak in the comparable set 10 (Oct 23 20:00)·Change over 24h in the comparable set –·Participants now 1

Participants counted1

Heat over time

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.